LY75

LY75 Molekülinformation

Englischer Name	Lymphocyte antigen 75	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1	Target-Alias	LY75，CD205，Lymphocyte Antigen 75，C-Type Lectin Domain Family 13 Member B，CLEC13B，DEC-205，CD205 Antigen，Gp200-MR6，Ly-75
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

Englischer Name	Lymphocyte antigen 75
Target-Alias	LY75，CD205，Lymphocyte Antigen 75，C-Type Lectin Domain Family 13 Member B，CLEC13B，DEC-205，CD205 Antigen，Gp200-MR6，Ly-75
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Phase 1 Clinical

LY75 Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Mouse (1)Human (1)
Etikett
His Tag (2)
Marker
Unconjugated (2)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
LY5-H52H3	Human	HEK293	Human LY75 / CD205 Protein, His Tag				In den Warenkorb legen
LY5-M52H5	Mouse	HEK293	Mouse LY75 / CD205 Protein, His Tag (MALS verified)				In den Warenkorb legen

Gesamtmenge2

LY75 Molekülhintergrund

lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.

LY75 Molekülalias

LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Oberotatug ravtansine	OBT-076; MEN1309/OBT076; MEN-1309	Phase 1 Clinical	Menarini, Oxford Biotherapeutics Ltd	Carcinoma, Adenoid Cystic; Head and Neck Neoplasms; Lymphoma, Non-Hodgkin; Solid tumours	Details